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Abstract (325/350 words) 
Background–Chloroquine (CQ) and Hydroxychloroquine (HCQ) have recently been 
suggested as treatment for the current Corona Virus Disease 2019 (COVID-19) pandemic. 
However, despite their long-term use and only few case reports on adverse effects, CQ 
and HCQ are listed as a known risk of the lethal ventricular arrhythmia Torsade de Pointes 
and their cardiac safety profile is being questioned. Thus, we aimed to investigate the 
electrocardiographic and mortality effects of CQ and HCQ in a primary care population. 
Methods–We used Danish health care registers and electrocardiograms (ECGs) from 
primary care to define three studies. 1) A paired study of subjects with ECGs before and 
during use of CQ/HCQ, 2) a matched ECG study of subjects taking CQ/HCQ compared to 
controls, and 3) a mortality study on people taking HCQ matched to control. In both 
matched studies, we adjusted for connective tissue diseases, use of QT-prolonging drugs, 
and cardiac disease. We used the QTc interval as the marker for electrocardiographic 
safety. In the mortality study, cases were followed from first claimed prescription until 300 
days after estimated completion of the last prescription. 95% confidence intervals follow 
estimates in parenthesis. 
Results–Use of CQ was associated with a 5.5 (0.7;10) ms increase in QTc in the paired 
study (n=10). In the matched study (n=28, controls=280), QTc was insignificantly 
increased in subjects taking CQ by 4.7 (-3.4;13) ms. 
With a ΔQTc of 1.0 (-5.6;7.5), use of HCQ was not associated with an increased QTc in 
the paired study (n=32). In the matched study (n=172, controls=1,720), QTc also was not 
different between groups (p=0.5). In the mortality study (n=3,368), use of HCQ was 
associated with a hazard ratio of 0.67 (0.43;1.05). 
Conclusions–In subjects free of COVID-19, we found a small increase in QTc associated 
with use of chloroquine, but not hydroxychloroquine. We found no increased mortality 
associated with use of hydroxychloroquine.  
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Introduction 
The Corona Virus Disease 2019 (COVID-19) pandemic has led to investigation and use of 
chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19. CQ and 
HCQ are 4-aminoquinilines approved for medical use in 1949 and 1955, respectively, and 
both drugs interfere with important physiological mechanisms that may improve the clinical 
course of patients with COVID-19. CQ and HCQ are weak bases and accumulate in 
lysosomes increasing pH which interferes with virus entry and fusion(1). CQ and HCQ also 
inhibit viral gene expression and post translational modification necessary for viral 
replication(1). Furthermore, CQ and HCQ have direct anti-inflammatory actions by 
inhibition of B- and T-cell receptors and especially by decreasing TNF-α and cytokine 
production (interleukin-1 and interleukin-6)(2). The drawback is that CQ and HCQ have 
known cardiotoxic effects(3) including vasodilatation, hypotension, hypokalemia, negative 
inotropy, and arrhythmias. The risk of arrhythmias may partly be mediated through the 
other cardiotoxic effect and partly due to ion channel blockade. Both CQ and HCQ are 
known hERG-blockers, but also block a variety of other ion channels including sodium, 
calcium, IK1 potassium and pacemaker funny channels(4). Since CQ and HCQ are old 
drugs, the approvals were granted long before thorough QT studies were required and 
only limited ECG safety data exists. Despite the known hERG block, there is a paucity of 
documented Torsades de Pointes ventricular tachycardia (TdP) during treatment,(5) which 
may be attributed to the concomitant calcium block protecting against TdP.(6) Only three 
cases of TdP have been published(7-9), all in patients with concomitant morbidities as 
cirrhosis, heart failure, or preexisting QT-prolongation. 
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Only limited electrocardiographic information is available of the effect of CQ/HCQ. A study 
of 14 healthy subjects receiving 1.5 g of CQ (normal dose in COVID 0.15 g OD(2)) found 
significant prolongation of the QT interval around 20 ms(10). With HCQ there does not 
exist any studies with comparable ECG data before and after treatment. Since COVID-19 
attacks the heart causing heart failure and even shock, it is unknown whether the 
arrhythmias seen in COVID-19 patients treated with HCQ/CQ are secondary to the 
disease or caused by the HCA/CQ treatment. Thus, an investigation of the 
electrocardiographic and mortality risks associated with CQ/HCQ treatment is needed. 
The aim of the present study was to investigate the effects of CQ/HCQ on 
electrocardiographic parameters in a large primary care population without COVID-19 
using Danish health care registers and electronic ECG data. 
 
Methods 
ECG 
The primary population consisted of 449,584 patients with 978,901 ECGs from the 
Copenhagen General Practitioners’ Laboratory (CGPL). CGPL was the core facility that 
received referrals from most General Practitioners in the Copenhagen area from 2001-
2015 for blood sampling and ECG examination. Data from CGPL was linked with Danish 
registries for a full patient history and follow-up. The Danish Civil Register contains 
information on sex, birthday, and emigration/permanent stays abroad. The Danish 
Register of Patient Records contains information on all hospital contacts (in-patient and 
out-patient). The Register used International Classification of Diseases, eighth revision 
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(ICD-8) codes until 1993 and ICD-10 codes from 1994. The Danish Register of Medication 
Statistics holds information on every claimed prescription from Danish pharmacies. The 
Danish Register of Causes of Death contains information on mortality for all Danish 
Citizens. 
Using the 12SL algorithm version 23 (GE Healthcare, Wauwatosa, WI), we obtained heart 
rate, QT interval, QRS duration, JT interval, PR interval, and presence of Right Bundle 
Branch Block (RBBB) or Left Bundle Branch Block (LBBB). The QT interval was corrected 
with Bazett (QTcB) and Framingham (QTcFrh) formulae. Based on the JT interval, JTc 
was obtained by linear correction for heart rate (JTc = JT – 119.4108*(RR-1), whereby RR 
is the R-to-R interval in seconds and JT is measured in ms). 
 
Studies and populations 
From the primary study population, we defined three subsets, each with a CQ and a HCQ 
population: 1) Paired study, 2) Matched study, and 3) Mortality study. As an additional 
analysis, we conducted a fourth study on connective tissue diseases with three 
populations independent of CQ/HCQ prescriptions. 
Paired study 
The Paired study is comprised of people with an ECG taken during a period of CQ or HCQ 
treatment, respectively, and with a prior baseline ECG without HCQ/CQ treatment. Thus, 
in this study, the subjects served as their own controls. 
Matched study 
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The Matched study is a comparison of subjects with an ECG taken during use of CQ or 
HCQ, respectively, compared to a matched reference population with no history of CQ and 
HCQ usage, respectively. Matching was done 10:1 on sex and age (rounded to integer 
years), sampled without replacement. 
Mortality study 
The Mortality study is a study of subjects with a prescription of HCQ matched 1:1 to sex- 
and age-matched controls with no prescription. Cases and their matched control were 
followed from the day of the first prescription until 300 days after predicted exhaustion of 
the last claimed prescription of the case. Since HCQ replaced CQ as the preferred drug in 
1995 with some but only few CQ prescriptions thereafter, the mortality study was not 
performed in the CQ group due to lack of power. 
RA/SLE/SS study 
The RA/SLE/SS study included subjects with and without rheumatoid arthritis (RA), 
systemic lupus erythematous (SLE), and Sjögren’s syndrome (SS), respectively. As in the 
Matched study on CQ and HCQ, we identified subjects with a diagnosis of RA, SLE, or SS, 
respectively, and matched them 1:1, 3:1, and 2:1 to controls, respectively, on sex and age 
(rounded to integer years), sampled without replacement. 
 
Medication and comorbidity 
Using Anatomical Therapeutic Chemical (ATC) codes, we identified use of CQ and HCQ. 
SLE, RA, SS, and ischemic heart disease were defined using the International 
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Classification of Diseases, 10th revision (ICD-10). Diabetes mellitus, hypertension, and 
congestive heart failure were all defined using a combination of ICD-10 and ATC codes at 
baseline as done previously.(11) Exact definitions using ICD-10 and ATC codes are given 
in the Supplementary Material. Use of QT-prolonging drugs was defined as concomitant 
prescription of one of the 63 drugs listed on CredibleMeds.org on April 30th 2020 as having 
a known risk of Torsade des Pointes (TdP, a possibly lethal polymorphic form of 
ventricular tachycardia) except for CQ and HCQ (see the Supplementary Material for the 
full list). 
 
Statistical considerations 
For subjects in the paired population, subjects served as their own controls and the results 
were thus inherently adjusted for comorbidity, age, and sex. We adjusted for a change in 
use of QT-prolonging drugs where appropriate. We used a random-effects regression 
model for continuous variables. 
For subjects in the matched population, we compared continuous electrocardiographic 
variables using linear regression crudely as well as with adjustment for RA, SLE, SS, use 
of QT-prolonging drugs, hypertension, ischemic heart disease congestive heart failure, and 
diabetes mellitus, as appropriate. Categorical variables were tested using a two-sample 
test of proportions. 
For subjects in the mortality population, we used Cox regression with full adjustment as 
with the matched population, as appropriate. Subjects were censored upon emigration 
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individually or 300 days after the last claimed prescription for each case/control pair. We 
used time-on-study as underlying time variable in the Cox model. 
The Danish Data Protection Agency approved the use of de-identified data (2007-58-0015) 
on the conditions that the exact number of subjects in groups of < 3 subjects not be 
disclosed and that no calculations (including p-values) be reported on groups of < 5 
subjects. All estimates were reported along with a 95 % confidence interval indicated as 
(lower to upper). Data management and statistical computations were performed in Stata 
(version 16), and a p-value < 0.05 was considered significant.  
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Results 
Paired study 
We identified ten subjects who had an ECG taken during a treatment of CQ and who had a 
prior ECG without treatment of CQ (Table 1, CQ population). Similarly, for treatment with 
HCQ, we identified 32 subjects (Table 1, HCQ population). 
Compared to their baseline ECG, subjects taking CQ had a significantly longer QTcFrh by 
5.5 ms (0.7 to 10, p=0.03). We found no evidence of an increased QTcFrh after use of 
HCQ (1.0 ms, -5.6 to 7.5 ms, p=0.8). 
 
Matched study 
We identified 28 and 172 subjects with an ECG taken during a period of treatment with CQ 
or HCQ, respectively, and matched them 10:1 with controls. 
Subjects on CQ (Table 2), compared to controls, were more likely to suffer from ischemic 
heart disease, but not hypertension. With full adjustment for RA, SLE, SS, QT-prolonging 
drugs, hypertension, diabetes, ischemic heart disease, and congestive heart failure, 
QTcFrh was 4.7 ms longer in the CQ group compared to control, but with a wide 
confidence interval (-3.4 to 13 ms, p=0.3). 
Subjects on HCQ (Table 3) more often than controls had RA, SLE or SS, as well as 
hypertension, ischemic heart disease, congestive heart failure, and diabetes. In the 
unadjusted analysis, we found an increased QTcFrh interval of 5 ms (p=0.002). However, 
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after adjustment for RA, SLE, SS and QT-prolonging drugs, there was no significant 
difference in QTcFrh between cases and controls (3.1 ms, -1.1 to 7.3 ms, p=0.15) and 
after additional adjustment for ischemic heart disease, hypertension, diabetes, and 
congestive heart failure, the difference in QTcFrh was reduced further to 1.3 ms (-2.9 to 
5.6, p=0.5). QRS duration followed a similar pattern in the adjusted and unadjusted 
analyses, whereas the JT interval also in the unadjusted analysis was comparable 
between the groups. 
 
Mortality study 
We identified 3,368 subjects with a prescription for HCQ irrespective of an ECG (Table 4). 
Subjects on HCQ were more likely to have RA, SLE, SS, hypertension, ischemic heart 
disease, and congestive heart failure. In the most crude analysis, adjusted only for sex and 
age, mortality was not different between subjects on HCQ and controls (HR=1.20, 0.85 to 
1.71, p=0.3). With adjustment for RA, SLE, SS, and use of other QT-prolonging drugs, we 
still found no significant difference between Hydroxychloroquine and matched controls 
(HR=0.80, 0.51 to 1.26, p=0.3). Further adjustment for ischemic heart disease, diabetes, 
hypertension, and congestive heart failure did not change the association materially. 
Kaplan-Meier survival curves are shown in Figure 1. 
 
RA/SLE/SS study 
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In the RA/SLE/SS study we defined three populations of cases and controls with and 
without RA, SLE, and SS respectively. We found no difference in crude or adjusted 
QTcFrh compared to control in any of the populations (Supplementary Tables 1-3). Heart 
rate was significantly higher in subjects with RA and SLE, but lower in subjects with SS. 
Crude PR interval was increased in subjects with SS, but not with adjustment for diabetes, 
ischemic heart disease, hypertension, and congestive heart failure. In the fully adjusted 
adjusted for sex, age, SS, SLE, QT-prolonging drugs, ischemic heart disease, diabetes, 
hypertension, and congestive heart failure, patients with RA had a shorter QRS duration 
compared to controls. 
 
 
Discussion 
In this real-world study, we found a small, but significant, heart rate-corrected 
QT-prolongation of 5 ms with CQ, but no QT prolongation with HCQ. We did not find 
increased mortality in subjects taking CQ or HCQ. 
 
Electrocardiographic safety 
CQ and HCQ are both listed as known causes of TdP on CredibleMeds.org,(12) and CQ is 
recognized by the World Health Organization (WHO) as prolonging the QT/QTc interval.(5) 
However, WHO states that CQ is associated with a low risk of cardiotoxicity based on 
PK/PD modelling.(5) In the present study, we found an increase in QTcFrh of 5.5 ms in the 
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paired CQ population, and no difference the paired HCQ population. Another study(10) 
showed that a 1,500 mg dose of CQ yielded an increase in QTc of 15-30 ms. 
Matched on sex and age, subjects receiving HCQ showed a 5 ms increase in QTcFrh. 
However, the increased QTc disappeared upon adjustment for use of QT-prolonging 
medication and connective tissue diseases. Hence, the increased QTcFrh was likely 
caused by rheumatic disease and not HCQ. Thus, in both the matched and the paired 
analyses, we were unable to demonstrate any statistically significant increase in QTc 
associated with use of HCQ. 
 
Mortality 
We did not find that use of HCQ was associated with an increased mortality. This is not 
surprising, since the toxicology profile of HCQ is better than that of CQ.(13) WHO reports 
that the few deaths associated with use of HCQ were caused by overdosing and chronic 
indications for HCQ.(5) 
Only three case studies have demonstrated arrhythmic adverse events in association with 
use of CQ/HCQ. One study(7) involved a syncope in a patient with SLE and end stage 
renal disease and QT prolongation before HCQ initiation. Another study(8) documents TdP 
in a patient with SLE, with a history of cirrhosis, HBV-related hepatoma, prior myocardial 
infarction, and ventricular septal defect. The third study(9) involved a patient with SLE, 
who also suffered from Congestive Heart Failure, Chronic Kidney Disease stage 5, and 
Hypertension. All three case studies thus features patients with severe QT-prolonging 
comorbidity and chronic rather than episodic use of Hydroxychloroquine. Collectively, 
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evidence from the present and other studies found little risk of death or arrhythmic events 
associated with episodic use of HCQ. 
 
Indication for HCQ 
Malaria was and still remains an indication for HCQ in Denmark, although it is no longer 
recommended.(14) HCQ is commonly prescribed for connective tissue diseases such as 
Rheumatoid Arthritis, Systemic Lupus Erythematous, and Sjögren’s Syndrome. We were 
only able to identify the reason for the HCQ treatment in forty to sixty percent of the cases, 
likely because milder connective tissue cases were treated in primary care and therefore 
never obtained a hospital ICD-10 diagnosis detectable in our registries. Furthermore, 
some subjects may have been prescribed HCQ as malaria prophylaxis. 
 
CQ and HCQ for treatment of COVID-19 
CQ/HCQ has emerged as a possible treatment for COVID-19.(15) Naturally, given the 
known risk of increased QTc, concerns about the safety of the drugs have been raised.(16, 
17) We have found different electrocardiographic safety profiles for CQ and HCQ. With 
CQ, we have demonstrated an increased QTcFrh of 5.5 ms. With HCQ, we found no 
increase in QTcFrh. For use of CQ and HCQ, respectively, we found no increased 
mortality. 
CQ and HCQ have been used as malaria prophylaxis for decades without raising red flags 
and the use of HCQ in higher doses to treat auto-immune diseases also has not been 
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associated with an increased mortality. The few case studies that exist were associated 
with chronic use of HCQ beyond the duration corresponding to a COVID-19 treatment and 
with severe QT-prolonging comorbidity. 
Arrhythmias are commonly seen in patients with COVID-19 (one study(18) reports 17 %) 
independently of treatment with CQ, HCQ, or azithromycin. The virus likely attacks the 
myocardium directly due to the high prevalence of angiotensin converting enzyme 2 
(ACE2) receptors in the heart.(19) Shi et al. found cardiac lesions (based on high-
sensitivity Troponin I) in 20 % of COVID-19 patient on admission.(20) There is no solid 
evidence for any significant proarrhythmic effects of CQ or HCQ. However, COVID-19 may 
play a super additive role in the safety profile of CQ/HCQ, and that can only be assessed 
with randomized studies on CQ/HCQ. 
The present study found no grounds for concern for HCQ and minor cautions for CQ in 
patients free of COVID-19. Saleh et al.(21) in 200 COVID-19 patients treated with 
CQ/HCQ plus 60 % azithromycin, found no cases of TdP, although seven patients 
discontinued treatment due to QT-prolongation. Mercuro et al.(16) found one case of TdP 
in 90 patients treated with HCQ or HCQ+azithromycin. Bessière et al.(17) found no cases 
of TdP in 40 patients treated with HCQ plus/minus azithromycin. A limitation of the present 
study is that we cannot exclude an interaction between COVID-19 and CQ/HCQ treatment, 
and thus further studies – preferably randomized clinical trials – are needed to assess the 
cardiac safety of CQ/HCQ in patients with COVID-19. 
 
Conclusions 
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Using matched and paired studies of subjects free of COVID-19 receiving chloroquine or 
hydroxychloroquine, we found that use of chloroquine but not hydroxychloroquine was 
associated with a small increase in QTc. We were unable to show increased mortality 
associated with hydroxychloroquine. 
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Tables 
Table 1. Paired population: ECG findings in subjects with ECG during a treatment with 
chloroquine or hydroxychloroquine. Reported are findings from a prior baseline ECG and 
change upon drug administration. 
Variables 
  
ECG before and during treatment 
Chloroquine Hydroxychloroquine 
n 10 32 
Age, years 61.6 ± 5.6 54.5 ± 12.1 
Sex, Females <3  24 (75 %) 
Baseline QT-prolonging drug aside from 
CQ/HCQ 
<3 4 (13 %) 
Study QT-prolonging drug aside from 
CQ/HCQ 
<3 6 (19 %) 
ECG variables   
Baseline Heart Rate, bpm 64.8 ± 14.7 70.9 ± 14.8 
ΔHeart Rate, bpm 1.3 [-5.6;8.2], p=0.7 2.3 [-1.7;6.2], p=0.3 
Baseline QTcB, ms 427 ± 30 432 ± 32 
ΔQTcB, ms 6.0 [-0.6;12.7], 
p=0.08 
2.4 [-6.3;11], p=0.6 
ΔQTcB > 30 ms <3 3 (9 %) 
Baseline QTcFrh, ms 421 ± 20 420 ± 23 
ΔQTcFrh, ms 5.5 [0.7;10], p=0.03 1.0 [-5.6;7.5], p=0.8 
ΔQTcFrh > 30 ms <3 <3 
Baseline JTc, ms 316 ± 22 317 ± 22 
ΔJTc, ms 2.8 [-3.3;8.9], p=0.4 -0.6 [-6.3;5.0], 
p=0.8 
Baseline QRS duration, ms 104 ± 21 98 ± 18 
ΔQRS duration, ms 2.2 [-1.4;5.8], p=0.2 0.2 [-3.7;4.0], p=0.9 
Baseline PR interval, ms 164 ± 24 164 ± 29 
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ΔPR interval, ms -0.4 [-9.1;8.2], 
p=0.9 
-2.8 [-9.4;3.8], 
p=0.4 
Baseline RBBB <3 <3 
Study RBBB <3 <3 
Baseline LBBB <3 <3 
Study LBBB <3 <3 
 
 
 
 
 
  
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 22, 2020. .https://doi.org/10.1101/2020.06.19.20135475doi: medRxiv preprint 
Table 2. Matched population: Characteristics and ECG findings in subjects taking 
chloroquine vs. control. For the ECG findings, adjusted models show effects independent 
of comorbidities. 
Variable Chloroquine Control p   
n 28 280    
Age, years 53.7 ± 14.0 53.6 ± 13.8    
Sex, females 11 (39 %) 110 (39 %)    
Rheumatoid Arthritis <3 5 (1.8 %)    
Systemic Lupus 
Erythematous 
<3 <3    
Sjögren’s Syndrome <3 <3    
Use of QT-prolonging 
drug+ 
<3 16 (6 %)    
Hypertension 6 (21 %) 55 (20 %) 0.8   
Ischemic Heart 
Disease 
7 (25 %) 20 (7 %) 0.001   
Congestive Heart 
Failure 
<3 <3    
Diabetes Mellitus 4 (14 %) 19 (7 %)    
ECG variables Chloroquine Control P Model 2* Δ/OR Model 3§ Δ/OR 
Heart rate, bpm 70.3 ± 15.9 71.9 ± 15.0 0.6 -1.8 [-7.6;4.1], 
p=0.6 
-1.7 [-7.8;4.4], 
p=0.6 
QTcB, ms 432 ± 27 429 ± 27 0.6 4.4 [-5.7;14], 
p=0.4 
2.9 [-7.4;13], 
p=0.6 
QTcFrh, ms 422 ± 21 417 ± 21 0.3 6.0 [-2.1;14], 
p=0.14 
4.7 [-3.4;13], 
p=0.3 
QTcB > 500 ms <3 <3  NA NA 
JTc, ms 318 ± 17 317 ± 20 0.8 2.0 [-5.5;9.5], 
p=0.6 
1.0 [-6.7;8.7], 
p=0.8 
PR interval, ms 162 ± 23 162 ± 23 0.9 0.9 [-7.9;9.8], 
p=0.8 
0.2 [-9.0;9.4], 
p=1.0 
QRS duration, ms 100 ± 20 96 ± 13 0.16 4.5 [-1.0;10], 
p=0.11 
4.2 [-1.5;9.8], 
p=0.15 
RBBB <3  4 (1.4 %)  Too few cases Too few cases 
LBBB <3  <3   Too few cases Too few cases 
*Adjusted for sex, age, Rheumatoid Arthritis, Systemic Lupus Erythematous, Sjögren’s Syndrome, and QT-
prolonging drugs+. §Adjusted for sex, age, Rheumatoid Arthritis, Systemic Lupus Erythematous, Sjögren’s 
Syndrome, QT-prolonging drugs+, Diabetes, Ischemic Heart Disease, Hypertension, and Congestive Heart Failure. 
+Excluding Chloroquine and Hydroxychloroquine 
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DP: Not disclosed due to data protection restrictions (groups of <5). NA: Not applicable. 
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Table 3. Matched population: Characteristics and ECG findings in subjects taking 
hydroxychloroquine vs. control. For the ECG findings, adjusted models show effects 
independent of comorbidities. 
Variable Hydroxy-
chloroquine 
Control  p   
n 172 1,720    
Age, years 59.8 ± 14.7 59.8 ± 
14.6 
   
Sex, females 120 (70 %) 1,200 
(70 %) 
   
Rheumatoid 
Arthritis 
76 (44 %) 17 (1.0 
%) 
<0.001   
Systemic 
Lupus 
Erythematous 
19 (11 %) <3 (<0.2 
%) 
   
Sjögren’s 
Syndrome 
8 (4.7 %) 4 (0.2 %)    
Use of QT-
prolonging 
drug+ 
16 (9 %) 95 (6 %) 0.04   
Hypertension 82 (48 %) 403 (23 
%) 
<0.001   
Ischemic 
Heart Disease 
31 (18 %) 112 (7 
%) 
<0.001   
Congestive 
Heart Failure 
12 (7 %) 29 (1.7 
%) 
<0.001   
Diabetes 
Mellitus 
26 (15 %) 141 (8 
%) 
0.002   
ECG 
variables 
Hydroxy-
chloroquine 
Control  p Model 2* 
Δ/OR 
Model 3§ 
Δ/OR 
Heart rate, 
bpm 
73.9 ± 14.3 72.5 ± 
14.4 
0.2 2.3 
[-0.7;5.3], 
p=0.13 
2.5 
[-0.6;5.5], 
p=0.11 
QTcB, ms 438 ± 26 432 ± 27 0.002 5.7 [0.2;11], 
p=0.04 
3.9 
[-1.6;9.5], 
p=0.16 
QTcFrh, ms 424 ± 22 419 ± 20 0.002 3.1 
[-1.1;7.3], 
p=0.15 
1.3 
[-2.9;5.6], 
p=0.5 
QTcB > 500 
ms 
4 (2.3 %) 22 (1.3 
%) 
 Too few 
cases 
Too few 
cases 
JTc, ms 323 ± 20 322 ± 21 0.5 -1.3 -1.1 
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[-5.5;2.8], 
p=0.5 
[-5.3;3.1], 
p=0.6 
PR interval, 
ms 
161 ± 27 160 ± 25 0.6 4.6 
[-0.3;9.5], 
p=0.07 
3.2 
[-1.8;8.2], 
p=0.2 
QRS duration, 
ms 
96 ± 16 92 ± 14 0.004 3.5 
[0.6;6.3], 
p=0.02 
1.4 
[-1.4;4.2], 
p=0.3 
RBBB 6 (3.3 %) 26 (1.5 
%) 
0.06 2.5 [0.7;9], 
p=0.17 
1.9 [0.5;7], 
p=0.4 
LBBB <3 9 (0.5 %)  Too few 
cases 
Too few 
cases 
*Adjusted for sex, age, Rheumatoid Arthritis, Systemic Lupus Erythematous, Sjögren’s Syndrome, and QT-
prolonging drugs+. §Adjusted for sex, age, Rheumatoid Arthritis, Systemic Lupus Erythematous, Sjögren’s 
Syndrome, QT-prolonging drugs+, Diabetes, Ischemic Heart Disease, Hypertension, and Congestive Heart 
Failure. +Excluding Chloroquine and Hydroxychloroquine 
DP: Not disclosed due to data protection restrictions (groups of <5). 
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Table 4. Mortality population: Baseline characteristics and mortality in subjects taking 
hydroxychloroquine compared to sex- and age-matched controls. 
Variable Hydroxychloroquine Control p 
n 3,368 3,368  
Age, years 53.1 ± 15.9 53.1± 15.9  
Sex, females 2,419 (72 %) 2,419 (72 %)  
Rheumatoid Arthritis 967 (29 %) 32 (1.0 %) <0.001 
Systemic Lupus 
Erythematous 
148 (4 %) 3 (0.9 %)  
Sjögren’s Syndrome 116 (3 %) 9 (0.3 %) <0.001 
QT-prolonging drugs* 274 (8 %) 150 (4 %) <0.001 
   QT-prolonging 
antibiotics 
116 (3.4 %) 11 (0.3 %) <0.001 
   QT-prolonging 
antidepressants 
116 (3.4 %) 102 (3.0 %) 0.3 
Hypertension 793 (24 %) 686 (20 %) 0.002 
Ischemic Heart 
Disease 
302 (9 %) 207 (6 %) <0.001 
Congestive Heart 
Failure 
59 (1.8 %) 29 (0.9 %) 0.001 
Diabetes Mellitus 219 (6.5 %) 222 (6.6 %) 0.9 
    
Risk of mortality, HR Hydroxychloroquine Control p 
Number of events 73 (2.2 %) 56 (1.7 %)  
Adjusted for sex and 
age 
1.20 (0.85-1.71) 1 0.3 
Adjusted for sex, age, 
RA, SLE, SS, and QT-
prolonging drugs* 
0.80 (0.51-1.26) 1 0.3 
Adjusted for sex, age, 
RA, SLE, SS, QT-
prolonging drugs*, 
HTN, IHD, CHF, DM 
0.79 (0.50-1.24) 1 0.3 
*Excluding chloroquine and hydroxychloroquine. Some statistics not disclosed due to 
data protection restrictions (groups of <5). RA, Rheumatoid Arthritis; SLE, Systemic 
Lupus Erythematous; SS, Sjögren’s Syndrome; HTN, Hypertension; IHD, Ischemic Heart 
Disease; CHF, Congestive Heart Failure; DM, Diabetes Mellitus. 
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FIGURES 
Figure 1. Survival for people on hydroxychloroquine and matched controls.  
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Supplemental material for 
Chloroquine, but not hydroxychlorquine prolongs the QT interval in a primary care 
population. 
Jonas L. Isaksen, Anders G. Holst, Adrian Pietersen, Jonas B. Nielsen, Claus Graff, 
Jørgen K. Kanters 
 
Supplemental methods 
Use of Chloroquine was defined when a prescription for Chloroquine (ATC code: 
P01BA01) was claimed. 
Use of Hydroxycloroquine was defined in the same way using ATC code P01BA02. 
Systemic Lupus Erythematous was defined as any of the ICD-10 codes DM32, DG058A, 
DG737C, DI328B, DI398C, DJ991C, or DN085A, or either ICD-8 code 695.4 or 734.1. 
Rheumatoid Arthritis was defined as any of the ICD-10 codes DM05 or DM06, or any of 
the ICD-8 codes 712.0, 712.1, or 712.3. 
Ischemic heart disease was defined as any of the ICD-10 codes I20, I21, I23, I24, I25 or 
the ICD-8 code 410. 
Diabetes mellitus was defined as any of the ICD-10 codes E10, E11, E12, E13 or E14, or 
use of insulin (ATC: A10A) or oral antidiabetics (ATC: A10B), or the ICD-8 code 761.1. 
Hypertension was present if any of the ICD-10 codes I10 or I15, or the ICD-8 code 401 
was found, or if we found concurrent use of two of these classes of medication: alpha 
blockers (ATC: C02A, C02B, C02C), non-loop diuretics (ATC: C02L, C03A, C03B, C03D, 
C03E, C03X, C07X, C07C, C07D, C08G, C02DA, C09BA, C09DA, C09XA52), 
vasodilators (ATC: C02DB, C02DD, C02DG, C04, C05), beta blockers (ATC: C07), 
calcium blockers (ATC: C08, C09BB, C09DB), or angiotensin converting enzyme inhibitors 
(ATC: C09). 
Heart failure was present if the ICD-10 codes I42, I50, or J81, or the ICD-8 code 427.0 
was found, or if a prescription of loop diuretics (ATC: C03C) was found. 
The following drugs and ATC codes were considered QT-prolonging in the present study. The list 
was taken from CredibleMeds.org on April 30, 2020 (revision March 19, 2020), and is comprised of 
those drugs categorized as having a known risk of Torsade de Pointes (TdP), with the omissions of 
Chloroquine and Hydroxychloroquine. 
Generic drug name ATC code(s) 
Aclarubicin L01DB04 
Amiodarone C01BD01 
Anagrelide L01XX35 
Arsenic trioxide L01XX27 
Astemizole R06AX11 
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Azithromycin J01FA10, S01AA26, J01RA07 
Bepridil C08EA02 
Cesium Chloride No ATC available 
Chlorpromazine N05AA01 
Chlorprothixene N05AF03 
Cilostazol B01AC23 
Ciprofloxacin J01MA02, S01AE03, S02AA15, S03AA07, J01RA10, J01RA11, 
J01RA12 
Cisapride A03FA02 
Citalopram N06AB04 
Clarithromycin J01FA09, A02BD04, A02BD05, A02BD06, A02BD07, A02BD09, 
A02BD11 
Cocaine N01BC01, R02AD03, S01HA01, S02DA02 
Disopyramide C01BA03 
Dofetelide C01BD04 
Domperidone A03FA03 
Donepezil N06DA02, N06DA52, N06DA53 
Dronedarone C01BD07 
Droperidol N05AD08 
Erythromycin D10AF02, J01FA01, S01AA17, D10AF52 
Escitalopram N06AB10 
Flecainide C01BC04 
Fluconazole D01AC15, J02AC01 
Gatifloxacin J01MA16, S01AE06 
Grepafloxacin J01MA11 
Halofantrine P01BX01 
Haloperidol N05AD01 
Hydroquinidine C01BA13 
Ibogaine No ATC available 
Ibutilide C01DB05 
Levofloxacin A02BD10, J01MA12, S01AE05, J01RA05 
Levomepromazine N05AA02 
Levomethadyl acetate N07BC03 
Levosulpride N05AL07 
Mesoridazine N05AC03 
Methadone N07BC02, N02AC52 
Moxifloxacin J01MA14, S01AE07 
Nifekalant Not marketed in Denmark 
Ondansetron A04AA01 
Oxaliplatin L01XA03 
Papaverine HCl A03AD01, G04BE02, G04BE52 
Pentamidine P01CX01 
Pimozide N05AG02 
Probucol C10AX02 
Procainamide C01BA02 
Propofol N01AX10 
Quinidine C01BA01, C01BA51, C01BA71 
Roxithromycin J01FA06 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 22, 2020. .https://doi.org/10.1101/2020.06.19.20135475doi: medRxiv preprint 
Sevoflurane N01AB08 
Sotalol C07AA07, C07FX02, C07BA07 
Sparfloxacin J01MA09 
Sulpride N05AL01 
Sultopride N05AL02 
Terfenadine R06AX12 
Terlipressin H01BA04 
Terodiline G04BD05 
Thioridazine N05AC02 
Vandetanib L01XE12 
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Supplementary Tables 
Supplementary Table 1. Characteristics and ECG findings in people with Rheumatoid Arthritis. 
Variable Rheumatoid 
Arthritis 
Control p   
n 6,329 6,329    
Age, years 64.2 ± 15.6 64.2 ± 15.6    
Sex, females 4,766 (75%) 4,766 (75%)    
Systemic Lupus 
Erythematous 
102 (1.6 %) 7 (0.1 %) <0.001   
Sjögren’s 
Syndrome 
144 (2.3 %) 22 (0.4 %) <0.001   
Use of QT-
prolonging 
drugs# 
619 (9.8 %) 414 (6.5 %) <0.001   
Hypertension 2,436 (38 %) 1,816 (29 %) <0.001   
Ischemic Heart 
Disease 
902 (14 %) 531 (9 %) <0.001   
Congestive 
Heart Failure 
370 (5.9 %) 186 (2.7 %) <0.001   
Diabetes 
Mellitus 
775 (12 %) 443 (7 %) <0.001   
ECG variables Rheumatoid 
Arthritis 
Control p Model 2* 
Δ/OR 
Model 3§ 
Δ/OR 
Heart rate, bpm 73.6 ± 14.4 73.0 ± 14.2 0.01 0.6 [0.1;1.1, 
p=0.01 
0.6 
[0.1;1.1], 
p=0.02 
QTcB, ms 434 ± 27 433 ± 27 0.07 0.6 [-0.3;1.5], 
p=0.2 
-0.2 
[-1.1;0.8], 
p=0.7 
QTcFrh, ms 420 ± 22 420 ± 22 0.4 0.1 [-0.7;0.9], 
p=0.8 
-0.6 
[-1.4;0.2], 
p=0.13 
QTcB > 500 ms 97 (1.5 %) 96 (1.5 %) 0.9 1.0 [0.7;1.3], 
p=0.9 
0.8 
[0.6;1.1], 
p=0.2 
JTc, ms 322 ± 23 322 ± 22 0.7 -0.1 
[-0.8;0.7], 
p=0.8 
-0.1 
[-0.9;0.6], 
p=0.7 
PR interval, ms 162 ± 27 161 ± 27 0.4 0.4 [-0.5;1.3], 
p=0.4 
-0.4 
[-1.3;0.5], 
p=0.4 
QRS duration, 
ms 
93 ± 16 93 ± 16 0.2 -0.1 
[-0.6;0.4], 
p=0.7 
-0.8 
[-1.2;-0.2], 
p=0.01 
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RBBB 141 (2.2 %) 133 (2.1 %) 0.6 1.1 [0.8;1.4], 
p=0.6 
1.0 
[0.8;1.3], 
p=0.9 
LBBB 45 (0.7 %) 60 (1.0 %) 0.14 0.8 [0.5;1.1], 
p=0.19 
0.7 
[0.5;1.1], 
p=0.09 
#Except Chloroquine and Hydroxychloroquine. *Adjusted for sex, age, Sjögren’s Syndrome, Systemic 
Lupus Erythematous, and QT-prolonging drugs#. §Adjusted for sex, age, Sjögren’s Syndrome, Systemic 
Lupus Erythematous, Diabetes, Ischemic Heart Disease, Hypertension, and Congestive Heart Failure. 
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Supplementary Table 2. Characteristics and ECG findings in people with Systemic Lupus 
Erythematous 
Variable Systemic 
Lupus 
Erythematous 
Control p   
n 540 1,620    
Age, years 56.4 ± 15.0 56.4 ± 15.0    
Sex, females 465 (86%) 1,395 (86 
%) 
   
Rheumatoid 
Arthritis 
97 (18 %) 18 (1.1 %) <0.001   
Sjögren’s 
Syndrome 
<3 9 (0.6 %)    
Use of QT-
prolonging 
drugs# 
54 (10 %) 96 (5.9 %) 0.001   
Hypertension 192 (36 %) 355 (22 %) <0.001   
Ischemic Heart 
Disease 
71 (13 %) 109 (7 %) <0.001   
Congestive Heart 
Failure 
23 (4.3 %) 29 (1.8 %) 0.001   
Diabetes Mellitus 40 (7.4 %) 85 (5.3 %) 0.06   
ECG variables Systemic 
Lupus 
Erythematous 
Control p Model 2* 
Δ/OR 
Model 3§ 
Δ/OR 
Heart rate, bpm 73.4 ± 14.1 71.8 ± 13.0 0.02 1.3 [-0.1;2.6], 
p=0.06 
1.3 
[-0.1;2.6], 
p=0.07 
QTcB, ms 433 ± 24 431 ± 25 0.08 2.0 [-0.5;4.5], 
p=0.11 
1.1 
[-1.4;3.6], 
p=0.4 
QTcFrh, ms 420 ± 19 419 ± 20 0.5 0.7 [-1.3;2.7], 
p=0.5 
-0.1 
[-2.1;1.9], 
p=0.9 
QTcB > 500 ms 3 (0.6 %) 11 (0.7 %)  Too few cases Too few 
cases 
JTc, ms 324 ± 20 324 ± 21 0.9 0.4 [-1.6;2.4], 
p=0.7 
0.1 
[-2.0;2.2], 
p=0.9 
PR interval, ms 158 ± 24 157 ± 25 0.6 1.2 [-1.4;3.7], 
p=0.4 
0.4 
[-2.2;3.0], 
p=0.8 
QRS duration, 
ms 
90 ± 13 90 ± 12 1.0 -0.2 [-1.4;1.1], 
p=0.8 
-0.7 
[-1.9;0.5], 
p=0.3 
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RBBB 4 (0.7 %) 14 (0.9 %)  Too few cases Too few 
cases 
LBBB <3  9 (0.6 %)  Too few cases Too few 
cases 
#Except Chloroquine and Hydroxychloroquine. *Adjusted for sex, age, Rheumatoid Arthritis, Sjögren’s 
Syndrome, and QT-prolonging drugs#. §Adjusted for sex, age, Rheumatoid Arthritis, Sjögren’s Syndrome, 
QT-prolonging drugs#, Diabetes, Ischemic Heart Disease, Hypertension, and Congestive Heart Failure. 
DP: Not disclosed due to data protection restrictions (groups of <5). 
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Supplementary Table 3. Characteristics and ECG findings in people with Sjögren’s 
Syndrome 
Variable Sjögren’s 
Syndrome 
Control p   
n 1,174 2,348    
Age, years 64.3 ± 14.1 64.3 ± 14.1    
Sex, females 1,042 (89%) 2,084 (89 
%) 
   
Rheumatoid 
Arthritis 
168 (14 %) 41 (1.8 %) <0.001   
Systemic Lupus 
Erythematous 
54 (4.6 %) 6 (0.3 %) <0.001   
Use of QT-
prolonging 
drugs# 
132 (11 %) 151 (6.4 %) <0.001   
Hypertension 467 (40 %) 677 (29 %) <0.001   
Ischemic Heart 
Disease 
184 (16 %) 198 (8.4 %) <0.001   
Congestive Heart 
Failure 
46 (3.9 %) 67 (2.9 %) 0.09   
Diabetes Mellitus 116 (9.9%) 170 (7.2 %) 0.007   
ECG variables Sjögren’s 
Syndrome 
Control p Model 2* 
Δ/OR 
Model 3§ 
Δ/OR 
Heart rate, bpm 72.3 ± 13.4 73.3 ± 13.7 0.04 -1.3 
[-2.3;-0.3], 
p=0.009 
-1.2 
[-2.2;-0.2], 
p=0.01 
QTcB, ms 433 ± 26 433 ± 26 0.4 -1.1 [-3.0;0.7], 
p=0.2 
-1.6 
[-3.4;0.3], 
p=0.10 
QTcFrh, ms 421 ± 21 420 ± 21 0.6 0.2 [-1.3;1.7], 
p=0.8 
-0.3 
[-1.8;1.3], 
p=0.7 
QTcB > 500 ms 8 (0.7 %) 30 (1.3 %) 0.11 0.6 [0.3;1.2], 
p=0.16 
0.5 
[0.2;1.1], 
p=0.09 
JTc, ms 325 ± 22 323 ± 21 0.16 0.9 [-0.7;2.4], 
p=0.3 
0.7 
[-0.8;2.3], 
p=0.4 
PR interval, ms 162 ± 25 160 ± 26 0.02 2.0 [0.2;3.9], 
p=0.03 
1.2 
[-0.6;3.1], 
p=0.20 
QRS duration, 
ms 
91 ± 15 91 ± 14 0.5 -0.1 [-1.2;0.9], 
p=0.8 
-0.5 
[-1.5;0.5], 
p=0.3 
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RBBB 24 (2.0 %) 37 (1.6 %) 0.3 1.3 [0.8;2.2], 
p=0.3 
1.2 
[0.7;2.1], 
p=0.5 
LBBB 9 (0.8 %) 25 (1.1 %) 0.4 0.7 [0.3;1.6], 
p=0.5 
0.7 
[0.3;1.6], 
p=0.4 
#Except Chloroquine and Hydroxychloroquine. *Adjusted for sex, age, Rheumatoid Arthritis, Systemic 
Lupus Erythematous and QT-prolonging drugs#. §Adjusted for sex, age, Rheumatoid Arthritis, Systemic 
Lupus Erythematous, QT-prolonging drugs#, Diabetes, Ischemic Heart Disease, Hypertension, and 
Congestive Heart Failure. 
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